📄 AIXCRYPTO HOLDINGS, INC.

Qualigen Therapeutics, Inc. is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. Its lead program, QN-302, is a small molecule G4-selective transcription inhibitor in a Phase 1a clinical trial for cancers like pancreatic cancer. The company also has a preclinical Pan-RAS program and a co-development agreement with Marizyme, Inc. for DuraGraft.

Qualigen Therapeutics, Inc. is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. Its lead program, QN-302, is a small molecule G4-selective transcription inhibitor in a Phase 1a clinical trial for cancers like pancreatic cancer. The company also has a preclinical Pan-RAS program and a co-development agreement with Marizyme, Inc. for DuraGraft.